Loading…

Intravenous administration of enprofylline to asthmatic patients

In 6 asthmatic patients, the possibility of obtaining a steady state plasma level of 5 mg/l of enprofylline by administration of two constant rate infusions was examined. The simulated plasma concentration curves, based on information from preassessment of individual pharmacokinetic parameters, were...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 1983-01, Vol.24 (3), p.323-327
Main Authors: Laursen, L C, Johannesson, N, Fagerström, P O, Weeke, B
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c348t-30a10030c5dd0fca8aae332e5f956ad45bc34addfc46a906780d9edbc36016823
cites cdi_FETCH-LOGICAL-c348t-30a10030c5dd0fca8aae332e5f956ad45bc34addfc46a906780d9edbc36016823
container_end_page 327
container_issue 3
container_start_page 323
container_title European journal of clinical pharmacology
container_volume 24
creator Laursen, L C
Johannesson, N
Fagerström, P O
Weeke, B
description In 6 asthmatic patients, the possibility of obtaining a steady state plasma level of 5 mg/l of enprofylline by administration of two constant rate infusions was examined. The simulated plasma concentration curves, based on information from preassessment of individual pharmacokinetic parameters, were in good agreement with the plasma levels obtained. The side-effects and bronchodilatation produced by enprofylline were compared to those obtained with theophylline at a steady state level of 15 mg/l. Enprofylline and theophylline caused a mean maximal increase in FEV1.0 of 14% and 2.6% per mg/l in plasma, respectively. Side-effects, headache, nausea and vomiting, became pronounced in 2 patients in whom the plasma enprofylline level was about 6 mg/l. No other serious adverse reaction was seen. It is suggested that enprofylline should be further evaluated as a possible anti-asthmatic drug.
doi_str_mv 10.1007/bf00610048
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00610048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6345176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-30a10030c5dd0fca8aae332e5f956ad45bc34addfc46a906780d9edbc36016823</originalsourceid><addsrcrecordid>eNo9kM1LxDAQxYMoa129eBdyFqqT5qPtTV1cXVjwoueS5gMrbVKSrLD_vZFdvcwMb34Mbx5C1wTuCEB931sAkSfWnKCCMFqVBBg5RQUAJaVoazhHFzF-ARDeAl2ghaCMk1oU6GHjUpDfxvldxFJPgxtiFtLgHfYWGzcHb_fjODiDk8cyps8pbxWeczUuxUt0ZuUYzdWxL9HH-vl99Vpu3142q8dtqShrUklBZoMUFNcarJKNlIbSynDbciE1433mpNZWMSFbEHUDujU6qwKIaCq6RLeHuyr4GIOx3RyGSYZ9R6D7TaF7Wv-lkOGbAzzv-snof_T4Nv0B8dFYRA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Intravenous administration of enprofylline to asthmatic patients</title><source>Springer Online Journal Archives (Through 1996)</source><creator>Laursen, L C ; Johannesson, N ; Fagerström, P O ; Weeke, B</creator><creatorcontrib>Laursen, L C ; Johannesson, N ; Fagerström, P O ; Weeke, B</creatorcontrib><description>In 6 asthmatic patients, the possibility of obtaining a steady state plasma level of 5 mg/l of enprofylline by administration of two constant rate infusions was examined. The simulated plasma concentration curves, based on information from preassessment of individual pharmacokinetic parameters, were in good agreement with the plasma levels obtained. The side-effects and bronchodilatation produced by enprofylline were compared to those obtained with theophylline at a steady state level of 15 mg/l. Enprofylline and theophylline caused a mean maximal increase in FEV1.0 of 14% and 2.6% per mg/l in plasma, respectively. Side-effects, headache, nausea and vomiting, became pronounced in 2 patients in whom the plasma enprofylline level was about 6 mg/l. No other serious adverse reaction was seen. It is suggested that enprofylline should be further evaluated as a possible anti-asthmatic drug.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/bf00610048</identifier><identifier>PMID: 6345176</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Asthma - drug therapy ; Clinical Trials as Topic ; Double-Blind Method ; Female ; Humans ; Infusions, Parenteral ; Kinetics ; Male ; Middle Aged ; Spirometry ; Theophylline - therapeutic use ; Xanthines - administration &amp; dosage ; Xanthines - adverse effects</subject><ispartof>European journal of clinical pharmacology, 1983-01, Vol.24 (3), p.323-327</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-30a10030c5dd0fca8aae332e5f956ad45bc34addfc46a906780d9edbc36016823</citedby><cites>FETCH-LOGICAL-c348t-30a10030c5dd0fca8aae332e5f956ad45bc34addfc46a906780d9edbc36016823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6345176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laursen, L C</creatorcontrib><creatorcontrib>Johannesson, N</creatorcontrib><creatorcontrib>Fagerström, P O</creatorcontrib><creatorcontrib>Weeke, B</creatorcontrib><title>Intravenous administration of enprofylline to asthmatic patients</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>In 6 asthmatic patients, the possibility of obtaining a steady state plasma level of 5 mg/l of enprofylline by administration of two constant rate infusions was examined. The simulated plasma concentration curves, based on information from preassessment of individual pharmacokinetic parameters, were in good agreement with the plasma levels obtained. The side-effects and bronchodilatation produced by enprofylline were compared to those obtained with theophylline at a steady state level of 15 mg/l. Enprofylline and theophylline caused a mean maximal increase in FEV1.0 of 14% and 2.6% per mg/l in plasma, respectively. Side-effects, headache, nausea and vomiting, became pronounced in 2 patients in whom the plasma enprofylline level was about 6 mg/l. No other serious adverse reaction was seen. It is suggested that enprofylline should be further evaluated as a possible anti-asthmatic drug.</description><subject>Adult</subject><subject>Asthma - drug therapy</subject><subject>Clinical Trials as Topic</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Parenteral</subject><subject>Kinetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Spirometry</subject><subject>Theophylline - therapeutic use</subject><subject>Xanthines - administration &amp; dosage</subject><subject>Xanthines - adverse effects</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><recordid>eNo9kM1LxDAQxYMoa129eBdyFqqT5qPtTV1cXVjwoueS5gMrbVKSrLD_vZFdvcwMb34Mbx5C1wTuCEB931sAkSfWnKCCMFqVBBg5RQUAJaVoazhHFzF-ARDeAl2ghaCMk1oU6GHjUpDfxvldxFJPgxtiFtLgHfYWGzcHb_fjODiDk8cyps8pbxWeczUuxUt0ZuUYzdWxL9HH-vl99Vpu3142q8dtqShrUklBZoMUFNcarJKNlIbSynDbciE1433mpNZWMSFbEHUDujU6qwKIaCq6RLeHuyr4GIOx3RyGSYZ9R6D7TaF7Wv-lkOGbAzzv-snof_T4Nv0B8dFYRA</recordid><startdate>19830101</startdate><enddate>19830101</enddate><creator>Laursen, L C</creator><creator>Johannesson, N</creator><creator>Fagerström, P O</creator><creator>Weeke, B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19830101</creationdate><title>Intravenous administration of enprofylline to asthmatic patients</title><author>Laursen, L C ; Johannesson, N ; Fagerström, P O ; Weeke, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-30a10030c5dd0fca8aae332e5f956ad45bc34addfc46a906780d9edbc36016823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Adult</topic><topic>Asthma - drug therapy</topic><topic>Clinical Trials as Topic</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Parenteral</topic><topic>Kinetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Spirometry</topic><topic>Theophylline - therapeutic use</topic><topic>Xanthines - administration &amp; dosage</topic><topic>Xanthines - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laursen, L C</creatorcontrib><creatorcontrib>Johannesson, N</creatorcontrib><creatorcontrib>Fagerström, P O</creatorcontrib><creatorcontrib>Weeke, B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laursen, L C</au><au>Johannesson, N</au><au>Fagerström, P O</au><au>Weeke, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous administration of enprofylline to asthmatic patients</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1983-01-01</date><risdate>1983</risdate><volume>24</volume><issue>3</issue><spage>323</spage><epage>327</epage><pages>323-327</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>In 6 asthmatic patients, the possibility of obtaining a steady state plasma level of 5 mg/l of enprofylline by administration of two constant rate infusions was examined. The simulated plasma concentration curves, based on information from preassessment of individual pharmacokinetic parameters, were in good agreement with the plasma levels obtained. The side-effects and bronchodilatation produced by enprofylline were compared to those obtained with theophylline at a steady state level of 15 mg/l. Enprofylline and theophylline caused a mean maximal increase in FEV1.0 of 14% and 2.6% per mg/l in plasma, respectively. Side-effects, headache, nausea and vomiting, became pronounced in 2 patients in whom the plasma enprofylline level was about 6 mg/l. No other serious adverse reaction was seen. It is suggested that enprofylline should be further evaluated as a possible anti-asthmatic drug.</abstract><cop>Germany</cop><pmid>6345176</pmid><doi>10.1007/bf00610048</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-6970
ispartof European journal of clinical pharmacology, 1983-01, Vol.24 (3), p.323-327
issn 0031-6970
1432-1041
language eng
recordid cdi_crossref_primary_10_1007_BF00610048
source Springer Online Journal Archives (Through 1996)
subjects Adult
Asthma - drug therapy
Clinical Trials as Topic
Double-Blind Method
Female
Humans
Infusions, Parenteral
Kinetics
Male
Middle Aged
Spirometry
Theophylline - therapeutic use
Xanthines - administration & dosage
Xanthines - adverse effects
title Intravenous administration of enprofylline to asthmatic patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A13%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20administration%20of%20enprofylline%20to%20asthmatic%20patients&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Laursen,%20L%20C&rft.date=1983-01-01&rft.volume=24&rft.issue=3&rft.spage=323&rft.epage=327&rft.pages=323-327&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/bf00610048&rft_dat=%3Cpubmed_cross%3E6345176%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c348t-30a10030c5dd0fca8aae332e5f956ad45bc34addfc46a906780d9edbc36016823%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/6345176&rfr_iscdi=true